HealthCap

Excellent news! 🚀 We congratulate the Vicore team on this important milestone. The FDA Grants Vicore’s Buloxibutid Fast Track Designation for Idiopathic Pulmonary Fibrosis www.healthcap.eu/mIFC

Oncopeptides’ Pepaxti formally approved for full reimbursement in Italy www.healthcap.eu/xTuI

Exciting News! 🚀Aro Biotherapeutics Doses First Patient in Phase 1b Trial of ABX1100 in Late-Onset Pompe Disease (LOPD) www.healthcap.eu/sUVy

For all orthopedic, trauma and podiatry surgeons on LInkedIn treating diabetic patients with osteomyelitis (bone infections): dramatic improvement in 5-year survival within the CERAMENT G/V(antibiotic eluting bone void filler) group: 87.5%, compared to 44.9% in the standard treatment group (no local antibiotic) [Mortality rate 12.5%, vs 55.1%, p<0.00001]. WOW Proud of the work of BONESUPPORT AB in bringing these products to the market. From the paper: NLAB no local antibx; LAC local antibx with CERAMENT G or CERAMENT V: Infection healing was demonstrated in 10 (20.41%) patients from group NLAB and 41 (73.21%) from group LAB (p < 0.0001). Persistence of infection with no evidence of wound healing, 6 months from surgery, was observed in 15 (30.61%) patients in group NLAB. Among the LAB group, only 4 (7.14%) patients demonstrated infection persistence (p = 0.00183). Reinfection was observed in 24 of 49 patients in group NLAB (49%) and in only 11 out of 56 patients in group LAB (20%) (p = 0.001466). 7 (6.67%) patients required major amputation with 6 (12.24%) belonging to group NLAB. Only 1 (1.78%) patient in group LAB underwent major amputation. A higher 5-year mortality rate was noted within patients in group NLAB, 27 (55.1%). The mortality rate in group LAB was (12.5%). This was a retrospective study, so has limitations of course. For disclosure I am on the board of BoneSupport which manufactures CERAMENT.

Exciting and important news - FDA Clears Ariceum Therapeutics’ 225Ac-Satoreotide Phase I/II Clinical Study in Patients with Small Cell Lung Cancer or Merkel Cell Carcinoma www.healthcap.eu/GHif

Ariceum Therapeutics and ITM Enter Supply Agreement for Therapeutic Medical Radioisotope Actinium-225 www.healthcap.eu/eHuz

CERAMENT® G AND CERAMENT® V contributes to improved survival rates BONESUPPORT™, a leading company in orthobiologics for the management of bone injuries, today announces strong study results for CERAMENT G and CERAMENT V in the surgical treatment of bone infection due to diabetic foot ulcers. The study is the first to document that surgical treatment with antibiotic eluting CERAMENT has contributed to increased survival rates over a 5-year period. The published clinical study included 105 patients with diabetic foot osteomyelitis that were either treated with surgical conventional treatment or surgical treatment including CERAMENT G or CERAMENT V. The results regarding infection healing, residual infection, re-infection, amputation, and mortality all showed significant advantages for the antibiotic eluting CERAMENT compared to standard treatment. The pioneering finding of the study was the dramatic improvement in 5-year survival within the CERAMENT group: 87.5%, compared to 44.9% in the standard treatment group [Mortality rate 12,5%, vs 55.1%, p<0.00001]. "By including the antibiotic eluting CERAMENT G and CERAMENT V in surgical treatment, we have improved infection statistics and dramatically reduced the risk of major amputations and mortality. Our hospital now uses antibiotic eluting CERAMENT as the standard treatment for diabetic foot," said Professor Anand Pillai, orthopedic and trauma surgeon at Manchester University Hospital and principal investigator of the study. Read full article here: https://bit.ly/3ZY4PxS 

Fantastic news from our portfolio company BONESUPPORT that today announces strong study results for CERAMENT G and CERAMENT V in the surgical treatment of bone infection due to diabetic foot ulcers showing that survival is significantly improved! www.healthcap.eu/yCdk

Fantastiskt bra. Vilken skjuts för detta intressanta projekt!

🌟 Enhancing Surgical Outcomes with CERAMENT® 🌟 "Identifying and modifying risk factors is essential for better outcomes," says Dr. Sebastian Meller, Charité Universitätsmedizin, Berlin, who shared insights from the CERAHip study using CERAMENT. Their findings showed remarkable success with no wound complications or secretion and significant improvements in patient pain, life quality, and HHS scores. Dr. Meller further mentioned that patient selection is paramount for high-risk patients requiring 1-stage revision. CERAMENT® G and CERAMENT® V have also become fundamental in the surgical protocols as bone graft substitutes with local antibiotics for defect augmentation in treating periprosthetic joint infections (PJI). 👉 Watch the full webinar here: https://bit.ly/480ivvY #BONESUPPORT #CERAMENT #SOLARIO #InfectionManagement #SymposiumOnDemand Disclaimer: The experts are independent, and the content is not influenced by BONESUPPORT™. Please refer to the Instructions for Use (IFU) document for official indications, contraindications, precautions and mixing information.